PT  - JOURNAL ARTICLE
AU  - David Li
AU  - Josephine Kang
AU  - Benjamin J. Golas
AU  - Vincent W. Yeung
AU  - David C. Madoff
TI  - Minimally invasive local therapies for liver cancer
AID  - 10.7497/j.issn.2095-3941.2014.04.001
DP  - 2014 Dec 01
TA  - Cancer Biology and Medicine
PG  - 217--236
VI  - 11
IP  - 4
4099  - http://www.cancerbiomed.org/content/11/4/217.short
4100  - http://www.cancerbiomed.org/content/11/4/217.full
SO  - Cancer Biol Med2014 Dec 01; 11
AB  - Primary and metastatic liver tumors are an increasing global health problem, with hepatocellular carcinoma (HCC) now being the third leading cause of cancer-related mortality worldwide. Systemic treatment options for HCC remain limited, with Sorafenib as the only prospectively validated agent shown to increase overall survival. Surgical resection and/or transplantation, locally ablative therapies and regional or locoregional therapies have filled the gap in liver tumor treatments, providing improved survival outcomes for both primary and metastatic tumors. Minimally invasive local therapies have an increasing role in the treatment of both primary and metastatic liver tumors. For patients with low volume disease, these therapies have now been established into consensus practice guidelines. This review highlights technical aspects and outcomes of commonly utilized, minimally invasive local therapies including laparoscopic liver resection (LLR), radiofrequency ablation (RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), irreversible electroporation (IRE), and stereotactic body radiation therapy (SBRT). In addition, the role of combination treatment strategies utilizing these minimally invasive techniques is reviewed.